2018-12-05 06:06:13 UTC
Britain came out on top as the most suitable site, thanks to its strong
science culture. The decision will support 650 jobs and means the UK
will remain home to one of UCB’s two global discovery research centres,
with the other being in Belgium.
A year ago the British government trumpeted similar investment
commitments by MSD, known as Merck & Co (MRK.N) in the United States,
and German-based diagnostics company Qiagen (QIA.DE).
The highly regulated drugs sector is one of the most vulnerable to
Britain’s decision to leave the EU because of uncertainty over how
medicines oversight will function in the event of an abrupt exit.
But pharmaceutical companies are still attracted by the country’s
world-class talent in biological science and its reputation as a
significant centre of drug development.